Abstract
Five metabolites of diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate (NO-1886) (1) were synthesized to confirm their proposed structures. The metabolites (2-6) were found to be identical with the synthesized compounds. These metabolites were orally administered to Triton WR-1339-induced hypertriglyceridemic rats, and the plasma levels of triglycerides were measured to estimate lipoprotein lipase activity. All the metabolites showed lower potency than NO-1886.
MeSH terms
-
Animals
-
Benzamides / chemistry
-
Benzamides / pharmacokinetics*
-
Benzamides / pharmacology*
-
Biotransformation
-
Chromatography, High Pressure Liquid
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacokinetics*
-
Enzyme Inhibitors / pharmacology*
-
Hyperlipidemias / blood
-
Hyperlipidemias / chemically induced
-
Hyperlipidemias / drug therapy
-
Lipoprotein Lipase / antagonists & inhibitors*
-
Magnetic Resonance Spectroscopy
-
Male
-
Organophosphorus Compounds / chemistry
-
Organophosphorus Compounds / pharmacokinetics*
-
Organophosphorus Compounds / pharmacology*
-
Polyethylene Glycols
-
Rats
-
Rats, Sprague-Dawley
-
Triglycerides / blood
Substances
-
Benzamides
-
Enzyme Inhibitors
-
Organophosphorus Compounds
-
Triglycerides
-
4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide
-
Polyethylene Glycols
-
Lipoprotein Lipase
-
tyloxapol